Transactions
15
Insider / BOSTON SCIENTIFIC CORP
O'Sullivan Miriam
SVP, Chief HR Officer at BOSTON SCIENTIFIC CORP
- Company
- BOSTON SCIENTIFIC CORP
- Ticker
- BSX
- First filing on record
- December 1, 2025
- Latest trade on record
- February 16, 2026
- SEC filings
- EDGAR ↗
O'Sullivan Miriam, SVP, Chief HR Officer at BOSTON SCIENTIFIC CORP, has disclosed 15 transactions in BSX since December 1, 2025: 0 purchases (0 open-market buys) and 4 sales, worth about $86K at the reported prices. The latest was filed February 18, 2026, 2 days after the trade; 8 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
4
Avg. disclosure lag
4.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months O'Sullivan Miriam made no purchases and 4 sales worth $86K, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
O'Sullivan Miriam has traded 1 stock on record; the largest by dollars is BSX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 7,326 | — |
| F | Shares withheld for tax | 4 | 1,158 | $86K |
| A | Grant or award | 2 | 15,865 | — |
| G | Gift | 1 | 260 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 14 | 0 | 4 · $86K |
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 990 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 1,124 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 588 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 16, 2026 | February 18, 2026 | 2d | 291 | $75 | $22K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 990 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 14, 2026 | February 18, 2026 | 4d | 329 | $75 | $25K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 1,124 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 13, 2026 | February 18, 2026 | 5d | 200 | $75 | $15K | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 588 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 11,143 | — | — | latederivative | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 4,722 | — | — | latederivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 961 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 12, 2026 | February 17, 2026 | 5d | 338 | $74 | $25K | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 961 | — | — | late | Form 4 ↗ | |
| BSX | Other G | November 28, 2025 | December 1, 2025 | 3d | 260 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| February 18, 2026 | Form 4 | 0001225208-26-002138 | 9 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0001225208-26-002021 | 5 | published | EDGAR ↗ |
| December 1, 2025 | Form 4 | 0001225208-25-009522 | 1 | published | EDGAR ↗ |
Other insiders at BOSTON SCIENTIFIC CORP
- Mahoney Michael F Chairman, President & CEO 30 rows
- Butcher Arthur C EVP& Grp Pres, MedSurg & APAC 29 rows
- Fitzgerald Joseph Michael EVP & Group Pres, Cardiology 28 rows
- O'Connor Padraig Andrew EVP, Global Operations 20 rows
- Monson Jonathan EVP and CFO 18 rows
- Woodworth Emily SVP, Global Controller and CAO 18 rows
- Brown Vance R EVP, GC and Corp. Secretary 16 rows
- Zane Ellen M Director 14 rows
- Smith Cathy R Director 11 rows
- Habiger David C Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: BOSTON SCIENTIFIC CORP.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 15 | December 1, 2025 | February 18, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.